Jubilant Pharmova Ltd announced a 65% increase in consolidated net profit, reaching Rs 102.5 crore for Q2 ending September 2024, driven by strong revenue growth. This is a significant rise from the Rs 62.1 crore net profit recorded in the same quarter last year, according to the company’s regulatory filing.
Consolidated revenue from operations grew to Rs 1,752.3 crore, up from Rs 1,680.3 crore in the previous year. Total expenses for the quarter also rose slightly to Rs 1,615.3 crore compared to Rs 1,601.2 crore a year earlier.
In another filing, Jubilant Pharmova shared that its U.S. subsidiary, Jubilant Pharma Holdings Inc., made an early payment of a USD 25 million (Rs 210 crore) term loan from internal funds on October 23, 2024. The company’s radiopharmaceuticals business, which supports diagnostics and treatments for conditions like cancer, hyperthyroidism, and lung diseases, contributed around 50% of the overall revenue and operates 52 radiopharmacies across the U.S.
Additionally, revenue from the company’s contract manufacturing division, its second-largest segment specializing in sterile injectables, saw a 5% increase. Jubilant Pharmova is a leading integrated pharmaceutical company that provides a broad range of solutions in the healthcare and life sciences sectors, serving clients worldwide.
With expertise spanning pharmaceuticals, contract research, and development, and radiopharmaceuticals, Jubilant Pharmova is dedicated to advancing human health through innovation and quality. The company’s offerings include active pharmaceutical ingredients (APIs), generics, specialty pharmaceuticals, and contract manufacturing, making it a vital partner for businesses in need of reliable, high-quality solutions.
Headquartered in India, Jubilant Pharmova has a strong global presence, operating multiple state-of-the-art facilities and research centers that adhere to stringent regulatory standards. Through a commitment to sustainable practices and advanced research, Jubilant Pharmova is recognized for its dedication to improving patient outcomes and supporting the healthcare sector’s evolving needs.
